Approved Hospital Formulary
Add Formweb to your mobile device
Search results for:
trastuzumab
trastuzumab
Brand names: Herceptin
| Form | Strength |
|---|---|
| POWDER FOR INJECTION, INTRAVENOUS | 440 mg |
Last updated: Jan. 9, 2024
- RCRA: Disposal
- RCRA: Management of Pharmaceutical Waste Policy
- Black Box Warning: Cardiomyopathy; infusion reactions, pulmonary toxicity; teratogenicity
- Restricted Restricted Medication
This medication is Inpatient Non-formulary and Restricted to Outpatient Use. Inpatient use requires approval by a physician department leader (i.e. Medical Director or Chair, or hospital CMO) collaborating with a pharmacy leader.
See HERE for more information and workflow.
See HERE for additional pharmacy workflow details.
May be given via hypodermoclysis (HDC/subcutaneous infusion). See Procedure 904.4991